The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Stands Pat on PMP Push, Says Minor Modification to Govt Proposal “Far from Sufficient”
December 8, 2017
- PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
- Hodanren Petitions Health and Finance Ministers to “Abolish the Price Maintenance Premium”
November 22, 2017
- Patrik Jonsson to Remain PhRMA Japan Chief as Pricing Reform Debate Continues
November 20, 2017
- Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
- Discussions on PMP Should Go Beyond Its Scope: JMA’s Imamura
November 10, 2017
- Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
November 6, 2017
- EFPIA Japan Chief Urges Govt to Maintain Support for Innovation
November 2, 2017
- Boehringer’s Thorsten Poehl Named EFPIA Japan Vice Chairman
October 31, 2017
- Global Pharma CEOs Prod Japan to Keep Pro-Innovation Policy, Sound Alarm on Proposed PMP Review
October 31, 2017
- PhRMA, EFPIA Upping Lobbying Campaigns amid Drug Pricing Overhaul
October 30, 2017
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- Securities Analysts Rank Shionogi No. 1 among Drug Markers for “Excellence in Disclosure”
October 17, 2017
- JMA President Yokokura Heads WMA
October 17, 2017
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- Taskforce Discussing Info-Sharing Between Drug Makers in Non-Competitive Fields: JPMA R&D Head
October 12, 2017
- Generic Use Rate at 67.8% in April-June: JGA
September 29, 2017
- Biologics Training Center to Start Human Resources Development in Biologics Field Next April
September 20, 2017
- Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
- Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…